|Systematic (IUPAC) name|
|Molar mass||378.546 g/mol|
AM-411 (part of the AM cannabinoid series) is an analgesic drug that is a cannabinoid agonist. It is a derivative of Δ8THC substituted with an adamantyl group at the 3-position, demonstrating that the binding pocket for the alkyl chain at this position can accommodate significant bulk.
AM-411 is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM, but is still also a moderately potent CB2 agonist with a Ki of 52.0nM. It produces similar effects to other cannabinoid agonists such as analgesia, sedation, and anxiolysis.
- Lu D, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. Journal of Medicinal Chemistry. 2005 Jul 14;48(14):4576-85. PMID 15999995
- Järbe TU, DiPatrizio NV, Lu D, Makriyannis A. (−)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behavioural Pharmacology. 2004 Nov;15(7):517-21. PMID 15472574
- McLaughlin PJ, et al. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology, Biochemistry and Behaviour. 2005 May;81(1):78-88. PMID 15894067
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|